OKYO Pharma Launches Public Share Offering to Fund Clinical Development

Event summary

  • OKYO Pharma intends to offer ordinary shares in an underwritten public offering, with an additional 15% option for the underwriter.
  • The offering is subject to market conditions and no assurances are given on completion or terms.
  • Proceeds will primarily fund clinical development of product candidates, general corporate purposes, and working capital.
  • The offering is made pursuant to a shelf registration statement on Form F-3, effective February 10, 2026.
  • OKYO recently completed a Phase 2 trial of urcosimod for neuropathic corneal pain (NCP) and plans a Phase 2b/3 study in 2026.

The big picture

OKYO Pharma's public offering reflects the strategic need for clinical-stage biopharmaceutical companies to secure funding amid high development costs and competitive pressures. The move comes as OKYO advances its lead candidate, urcosimod, through critical clinical trials, positioning the company for potential regulatory milestones in the treatment of neuropathic corneal pain and inflammatory eye diseases. The success of this offering will be a key indicator of investor confidence in OKYO's pipeline and execution capabilities.

What we're watching

Funding Execution
Whether OKYO can successfully complete the offering and secure sufficient proceeds to advance its clinical pipeline.
Clinical Milestones
The pace at which OKYO progresses its Phase 2b/3 study of urcosimod and the potential for regulatory approval.
Market Conditions
How market volatility and investor sentiment may impact the size and terms of the offering.

Related topics

Clinical Trial